Antisense modulation of integrin beta 4 binding protein expression

Abstract

Antisense compounds, compositions and methods are provided for modulating the expression of Integrin beta 4 binding protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Integrin beta 4 binding protein. Methods of using these compounds for modulation of Integrin beta 4 binding protein expression and for treatment of diseases associated with expression of Integrin beta 4 binding protein are provided.

1 . A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding Integrin beta 4 binding protein, wherein said compound specifically hybridizes with and inhibits the expression of Integrin beta 4 binding protein.  
     
     
         2 . The compound of  claim 1  which is an antisense oligonucleotide.  
     
     
         3 . The compound of  claim 2  wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 12, 13, 14, 15, 17, 18, 19, 20, 21, 22, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 45, 47, 49, 50, 52, 53, 54, 55, 56, 57, 58, 59, 60, 63, 64, 65, 67, 68, 69, 70, 72, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87 or 88.  
     
     
         4 . The compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.  
     
     
         5 . The compound of  claim 4  wherein the modified internucleoside linkage is a phosphorothioate linkage.  
     
     
         6 . The compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified sugar moiety.  
     
     
         7 . The compound of  claim 6  wherein the modified sugar moiety is a 2′-O-methoxyethyl sugar moiety.  
     
     
         8 . The compound of  claim 2  wherein the antisense oligonucleotide comprises at least one modified nucleobase.  
     
     
         9 . The compound of  claim 8  wherein the modified nucleobase is a 5-methylcytosine.  
     
     
         10 . The compound of  claim 2  wherein the antisense oligonucleotide is a chimeric oligonucleotide.  
     
     
         11 . A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding Integrin beta 4 binding protein.  
     
     
         12 . A composition comprising the compound of  claim 1  and a pharmaceutically acceptable carrier or diluent.  
     
     
         13 . The composition of  claim 12  further comprising a colloidal dispersion system.  
     
     
         14 . The composition of  claim 12  wherein the compound is an antisense oligonucleotide.  
     
     
         15 . A method of inhibiting the expression of Integrin beta 4 binding protein in cells or tissues comprising contacting said cells or tissues with the compound of  claim 1  so that expression of Integrin beta 4 binding protein is inhibited.  
     
     
         16 . A method of treating an animal having a disease or condition associated with Integrin beta 4 binding protein comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of  claim 1  so that expression of Integrin beta 4 binding protein is inhibited.  
     
     
         17 . The method of  claim 16  wherein the disease or condition is a hypoproliferative disorder.  
     
     
         18 . The method of  claim 17  wherein the hypoproliferative disorder is cancer.  
     
     
         19 . The method of  claim 18  wherein the cancer is colorectal.  
     
     
         20 . The method of  claim 16  wherein the disease or condition is inflammation.